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Induction of ventricular arrhythmia by high and 
low osmotarity ionic and nonionic contrast 
media 
Studies that used prolonged contrast media infusion in canine arteries have generated 
controversy regarding the arrhythmogenic potential of low osmoiarity, nonionio contrast agents. 
in order to establish the relative safety of these agents in the more typical setting of boius 
injections, 4 mll intracoronary btilus injections of Hypaqus76 (n = 54), iohexoi-350 (n = 51), and 
iohexoi-140 (n = 51) were given in random order to 10 anesthetized, open-chest dogs undergoing 
programmed cardiac stimuiation. Hemodynamics and electrocardiogram were monitored during 
stimulation, both during and for 2 minutes after the end qf contrast hifusion. Occurrence of 
evoked sfngie and coupled premature ventricular cur&actions and nonsustained ventricular 
tachyqardia did not d&fer statistically among agents. Sustained ventricular tachycardia (five 
episodes) and w~ntricuiar fibrillation (seven episodes) occurred only after Hypaqua76 injections 
@ < 0.002). Thase results differ from those in studies that use ctitinuous contrast infusiog and 
suggest that iow osmoiarity nonionic contrast agents are as safe as high osmolarity nonionic 
contrast media. Both appear safer than ionic contrast material. (AM ‘HEART J 1969;117:1263.) 
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Many studies14 document the hemodynamic and 
electrocardiographic effecta of ionic and nonionic 
contrast agents, and report fewer adverse effects 
with nonionic contrast media. Hyperosmolarity has 
been implicated as a major determinapt of toxicity, 
but studies that used prolonged infusions of nonioq- 
ic isoosmolar agents have contested the safety of 
such agents with respect to induction of ventricular 
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Fig. 1. Tracings recorded during observations. From top to bottom are shown left ventricular pressure, 
its first derivative dP/dt, and end-diastolic nressure. The electrocardiogram and stimulation protocol are 
recorded in the fourth tracing. 








Hypaque-76 Iohexol-350 Iohexol-I40 
2100.0 862.0 322 
13.3 18.5 2.0 
370.0 350.0 140 
Sodium Calcium Calcium 
(3.7 mg/ml) (0.1 mg/ml) (0.1 mg/ml) 
arrhythmia.7-10 The clinical relevance of such studies 
is questionable, however, since intracoronary con- 
trast infusion for diagnostic and intervention pur- 
poses is usually performed with rapid bolus injec- 
tions rather than with prolonged infusions. The 
present study compares the arrhythmogenicity of 
bolus injections of high and low osmolarity nonionic 
agents and ionic contrast media. 
METHODS 
Ten mongrel dogs (mean weight 21.9 kg) were anesthe- 
tized with 35 mg/kg of sodium pentobarbital and venti- 
lated with a Harvard pump (15 ml/kg) (Harvard Appara- 
tus Inc., S. Natick, Mass.). The left carotid artery and the 
left jugular vein were dissected for vascular access. A left 
thoracotomy was performed in the fifth intercostal space, 
the pericardium was incised, and the heart was exposed. 
Needle electrodes were inserted subcutaneously to moni- 
tor the electrocardiogram A 5F micromanometer (Millar 
Instruments, Inc., Houston, Texas) was inserted into the 
left ventricle, via apical puncture, to monitor left ventric- 
ular pressure and its first derivative (dP/dt). 
Two leads were clipped onto the surface of the right 
atrium and two leads were sutured to the left ventricle. 
These leads were connected to a cardiac stimulator (Mod- 
el DTU-110, Bloom Associates, Narberth, Pa.) for pro- 
grammed pacing. All animals were pretreated with pro- 
pranolol(l mg/kg) and atropine (1 mg) to reduce effects of 
sympathetic and parasympathetic tone on heart rate and 
function. 
Programmed stimulation consisted of atrial pacing fol- 
lowed by three ventricular extrastimuli. The atria1 pacing 
rate was selected at 5 to 10 beats faster than the intrinsic 
heart rate and a stable 1: 1 atrioventricular (AV) conduc- 
tion was maintained. At the end of a four-beat train of 
atria1 pacing, diastole was scanned with a single extrastim- 
ulus (S,). The S, was started late in diastole and moved 
toward the basic drive train at 10 msec intervals until the 
S, repeatedly failed to stimulate the ventricle. The inter- 
val between the last QRS (S,) complex of the basic train 
and S, was defined as the ventricular effective refractory 
period (ERP) and S, was delivered 10 msec beyond it. A 
second extrastimulus (S,) interval followed SZ, and the 
initial coupling interval was equal to S,-S,. The S,-S, 
interval was reduced to 10 msec steps until S, failed to 
provoke a ventricular response. The S,-S, interval was 
defined as the S, ERP, and S, was delivered 10 msec after 
S, ERP. Diastole was scanned with a third extrastimulus 
(S,). S, was first introduced with a coupling interval equal 
to S,-S, and subsequently reduced in 10 msec steps until 
S, failed to provoke a ventricular response. The S,-S, 
interval was defined as the S, ERP, and S, was delivered 
10 msec after this. A 2-second interval separated delivery 
of each train of atria1 and ventricular extrastimuli. 
The left coronary artery was catheterized with a 5F or 
6F catheter, and a bolus injection of 4 ml of either 
Hypaque-76, Iohexol-350, or Iohexol-140 was given in 
random order during a 2-minute repetitive stimulation of 
the protocol established above (Table I). The limb lead II 
of the electrocardiogram, left ventricular pressure, and 
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Table II. QT interval and hemodynamic parameters 
Iohexol-140 Zohenol-350 Hypoque-76 
QT interval 0 225 f 20 222 f 21 223 k 21 
min 
QT interval 1 222 + 22 221 + 23 229 k 24 
min 
QT interval 2 219 rt 20 218 f 20 225 k 18 
min 
SBP 143 * 17 146 k 15 141 + 19 
EDP 9+2 9k3 9+3 
Peak + dP/dt 2405 k 559 2379 ~fr 525 2485 + 702 
Peak - dP/dt 2011 ? 258 2077 + 253 2062 fz 355 
SBP, Systolic blood pressure; EDP, end-diastolic pressure; +, positive; -, 
negative. 
dP/dt were recorded (Model 28OOS, Gould Electronics, 
Cleveland, Ohio) (Fig. l), before and for 2 minutes after 
injection of each agent. Tracings at 100 mm/set paper 
speed were recorded before injection and at 1 and 2 
minutes after injection for QT interval measurements. 
Each agent was injected three times, and the period of 
injection was precisely recorded. A 4-minute resting peri- 
od separated each test. 
When sustained ventricular tachycardia or ventricular 
fibrillation occurred, defibrillation was attempted with a 
cardiac defibrillator (Mennen-Greatbatch Electronics, 
Clarence, N.Y.), set at 50 joules and applied directly to the 
heart. When defibrillation was required, further testing of 
the agents was suspended for at least 20 minutes. In eight 
dogs, the entire sequence of drug testing was repeated a 
second time. In two dogs, the sequence could not be 
completed due to unsuccessful defibrillation. 
Tracings were analyzed for systolic blood pressure, left 
ventricular end-diastolic pressure, dP/dt, heart rate, QT 
interval, occurrence of single premature ventricular con- 
tractions, ventricular couplets, nonsustained ventricular 
tachycardia (defined as a sequence of at least three 
premature ventricular contractions that lasted no more 
than 30 seconds and spontaneously resolved), sustained 
ventricular tachycardia (defined as ventricular tachycar- 
dia lasting longer than 30 seconds or requiring treatment 
for resolution:), and ventricular fibrillation (defined as 
gross irregularity of the QRS complex and hemodynamic 
deterioration). 
Hypothesis testing of frequency data was carried out by 
means of a clni square statistic’l ‘Continuous variables 
were analyzed with BMDPSV statistical software (Bio- 
medical Data Package, UC Press, Berkeley, Calif.) for 
mixed model unbalanced designs.‘* A modified t test 
(Bonferroni) was used to assess specific differences from 
control values.‘3 Data not normally distributed were ana- 
lyzed with a Kruskal Wallis test. Results were considered 
significant when p < 0.05. 
RESULTS 
Hypaque-76 was injected 54 times, and Iohexol- 
350 and Iohexol-140 were injected 51 times. The 
numbers differ because two dogs died during Hypa- 
que-induced arrhythmia. Boluses were injected by 
bBl¶ SINGLE VENTRICULAR ECTOPIC BEATS 
EiZd COUPLED VENTRICULAR ECTOPIC BEATS 
tZ3 NSVT 
T 
W SVT/VF (~(0.02) 
WEXOL-140 IOHEXOL-350 HYPMUE-76 
CONTRAST INFUSION 
Fig. 2. Incidence of single and coupled ectopic beats, 
nonsustained (NSVT) and sustained @VT) ventricular 
tachycardia for total observations of Iohexol-140, Iohexol- 
350, and Hypaque-76 injections. The five episodes of SVT 
after Hypaque-76 injections degenerated into ventricular 
fibrillation and are shown in the same graph. 
hand as rapidly as possible, but because of viscosity 
differences, the injection duration differed for each 
agent. Mean infusion duration for Hypaque-76 was 
3.2 + 1.3 seconds (*SD), for Iohexol-350 it was 
3.2 + 1.3 seconds, and for Iohexol-140 it was 1.5 f 
0.5 seconds (p = NS). QT interval differences were 
not significant at 1 and 2 minutes after injection. 
Hemodynamics parameters (systolic and end-dia- 
stolic pressure, dP/dt) were similar among all groups 
(Table II). Temporal stability of each preparation 
was confirmed with a paired t test of pre- and 
post-protocol .basal pressures, dP/dt, and heart 
rate; no statistically significant changes were 
noted. 
The incidence of evoked single and coupled pre- 
mature ventricular contractions was not statistically 
different after infusion of any agent (Fig. 2j. Simi- 
larly, the incidence of nonsustained ventricular 
tachycardia was not significantly different-7 in 54 
Hypaque-76 observations, 5 in 51 Iohexol-350 obser- 
vations, and 1 in 51 Iohexol-140 observations, 
p = NS. Sustained ventricular tachycardia occurred 
only after Hypaque-76 injections (5 episodes in 54 
injections, p = 0.02), and degenerated into ventricu- 
lar fibrillation each time. 
Ventricular fibrillation occurred only after Hypa- 
que-76 injections. While five episodes were a conse- 
quence of sustained ventricular tachycardia, two 
were primary events. Thus there were seven epi- 
sodes of ventricular fibrillation after 54 Hypaque-76 
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injections (12.9 % ), and this was significantly greater 
than with the other agents 0, = 0.02). Cardioversion 
was successful in five of seven episodes. 
DISCUSSION 
Harmful effects of contrast agents are extensively 
described.‘p3v 14-lg Suggested mechanisms that may 
induce these reactions include protein binding and 
inactivation of enzymatic function, deformation of 
erythrocyte morphology, complement activation, 
and direct cardiotoxicity.*, 14-17, 2o In addition, the 
presence of ethylenediamine tetraacetic acid 
(EDTA) and sodium citrate in some formulations 
may facilitate induction of arrhythmia.z*r22 Nonionic 
contrast media may alleviate some of these adverse 
reactions.23-26 They stimulate inducing mechanisms 
to a lesser degree, and several studies suggest that 
they induce fewer undesirable hemodynamic and 
electrocardiographic changes.27-34 
Another long recognized potential inducer of 
adverse effects is hyperosmolarity. Several re- 
ports6~23~27 have shown that low osmolarity contrast 
agents induce even less significant hemodynamic 
changes than standard media. Although their 
arrhythmogenicity has seldom been tested, some 
evidence34 suggests that nonionic, low oemolarity 
contrast media induce fewer arrhythmias than con- 
ventional agents. However, some studies7vh 1o,35 cre- 
ated controversy by suggesting that ionic and high 
osmolarity contrast media are safer. These conflict- 
ing studies differ predominantly in the method of 
contrast injection. Studies that showed adverse 
effects of low osmolarity contrast agentsg,10,35 have 
routinely used high doses and prolonged infusions of 
contrast agents. 
The current study is an attempt to simulate a 
more typical clinical situation by assessing the 
effects of rapid bolus hand injections. To potentiate 
the arrhythmogenicity of the contrast agents and to 
mimic a high-risk state,36 the heart was subjected to 
repeated ventricular stimulation. Thus sustained 
ventricular tachycardia and ventricular fibrillation 
occurred only after Hypaque-76 injections. Previous 
reporb14, 22-24.34 h s ow a smaller arrhythmogenic pro- 
pensity of Iohexol-350 compared to standard ionic 
agents, but this is the first time that the arrhythmo- 
genicity of Iohexol-140 has been compared to that of 
Iohexol-350 and Hypaque-76. The results show that 
the arrhythmogenicity of Iohexol-140 is comparable 
to that of Iohexol-350 and that both are significantly 
less arrhythmogenic than Hypaque-76. 
These data confirm that nonionic contrast media 
are an attractive option for high-risk situations. The 
comparable results of Iohexol-140 to Iohexol-350 in 
Juno 1999 
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this study offers an impetus for further evaluation of 
low osmolarity nonionic media in the setting of 
cardiac catheterization. While some such agents are 
currently being used in Europe with reports of 
improved patient tolerance,37 studies addressing the 
quality of coronary and ventricular images when low 
osmolarity agents are used will be required. 
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